We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+1.52%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$887M
AUM Growth
-$223M
(-20%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-11.56%
Top 10 Holdings %
Top 10 Hldgs %
73.36%
Holding
40
New
6
Increased
12
Reduced
9
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLRN
ACELYRIN
SLRN
|
+$13M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$4.73M |
| 3 |
ELEV
Elevation Oncology
ELEV
|
+$4.36M |
| 4 |
AnaptysBio
ANAB
|
+$2.68M |
| 5 |
BLUE
bluebird bio
BLUE
|
+$1.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$32.8M |
| 2 |
Insmed
INSM
|
+$30.5M |
| 3 |
United Therapeutics
UTHR
|
+$28.9M |
| 4 |
Biogen
BIIB
|
+$21.2M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$13.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.15% |
| 2 | Financials | 1.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ELEV
26
DELISTED
Elevation Oncology
ELEV
| $6.91M | 0.78% |
+1,346,666
| New | +$4.36M |
|
|
BLUE
27
DELISTED
bluebird bio
BLUE
| $5.84M | 0.66% |
228,009
+61,342
| +37% | +$1.57M |
|
28
Relmada Therapeutics
RLMD
$503M
| $3.41M | 0.38% |
732,400
| – | – |
|
29
Nuvation Bio
NUVB
$2.25B
| $2.81M | 0.32% |
+772,652
| New | +$1.48M |
|
30
Taysha Gene Therapies
TSHA
$2.05B
| $2.33M | 0.26% |
811,268
+281,407
| +53% | +$586K |
|
31
Stoke Therapeutics
STOK
$2.13B
| $1.7M | 0.19% |
+125,861
| New | +$763K |
|
32
Mirum Pharmaceuticals
MIRM
$6.04B
| $1.63M | 0.18% |
64,700
| – | – |
|
33
Humana
HUM
$46.7B
| $1.38M | 0.16% |
+3,985
| New | +$1.51M |
|
|
YARW
34
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
| $1.37M | 0.15% |
8,909
| – | – |
|
35
Travere Therapeutics
TVTX
$5.86B
| $854K | 0.1% |
110,719
| – | – |
|
36
Aldeyra Therapeutics
ALDX
$91.7M
| $737K | 0.08% |
225,465
| – | – |
|
37
Aclaris Therapeutics
ACRS
$860M
| $707K | 0.08% |
+569,832
| New | +$680K |
|
38
UroGen Pharma
URGN
$2.39B
| $368K | 0.04% |
24,500
| – | – |
|
39
Sight Sciences
SGHT
$456M
| – | – |
-173,790
| Closed | -$897K |
|
40
Vanda Pharmaceuticals
VNDA
$314M
| – | – |
-278,985
| Closed | -$1.18M |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q1 2024 Portfolio in Review
As of Q1 2024, Palo Alto Investors held 40 positions worth $887M, down 20% from $1.11B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Palo Alto Investors withdrew a net $103M in Q1 2024, closing 2 positions and reducing 9 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $1.18M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.
Against the trend, Palo Alto Investors opened a new position in ACELYRIN worth $11.6M.
- Palo Alto Investors's largest Q1 2024 buy was ACELYRIN: 1,715,180 shares worth $11.6M.
- Palo Alto Investors added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $4.73M increase.
- Palo Alto Investors's biggest Q1 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $32.8M.
- Palo Alto Investors fully exited Vanda Pharmaceuticals in Q1 2024, selling an estimated $1.18M.
- Palo Alto Investors's ten largest holdings make up 73% of its $887M portfolio in Q1 2024.
- Palo Alto Investors opened 6 new positions and closed 2 in Q1 2024.
- Palo Alto Investors's portfolio value fell 20% quarter-over-quarter to $887M.
Based on Palo Alto Investors's 13F filing for Q1 2024, filed 15 May 2024.